A Study to Assess Frequency of Undetectable Minimal Residual Disease (uMRD) in Adult Participants With Chronic Lymphocytic Leukemia (CLL) Receiving Oral Venetoclax Tablets ± Intravenously (IV) Infused Rituximab in Routine Clinical Practice in Japan

Conditions: Chronic Lymphocytic Leukemia Sponsors: AbbVie Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials